BioSpace News Archive

Zynerba Pharmaceuticals, Inc., the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, announced the acceptance and oral presentation details of two sets of data at The Society for the Study of Behavioural Phenotypes Conference 2021, which will be held virtually from September 9-10, 2021.

NextCure, Inc., a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, announced that it will participate in a fireside chat at the 19th Annual Morgan Stanley Global Healthcare Conference on September 9th at 12:30 pm Eastern time.

CareDx, Inc., a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, announced the Company plans to participate in the 2021 Wells Fargo Healthcare Conference and H.C. Wainwright 23rd Annual Global Investment Conference.

Bio-Techne Corporation announced that Chuck Kummeth, President and Chief Executive Officer, will present at the 2021 Virtual Wells Fargo Healthcare Conference on Thursday, September 9, 2021 at 2:00 p.m. EDT.

Virios Therapeutics, Inc. announced that Greg Duncan, Chairman and Chief Executive Officer, will present a company overview at the H.C. Wainwright 23rd Annual Global Investment Conference which is taking place virtually September 13 – 15, 2021.

Deciphera Pharmaceuticals, Inc. announced that Steve Hoerter, President and Chief Executive Officer, will participate in a fireside chat at the 19th Annual Morgan Stanley Global Healthcare Conference on September 9, 2021 at 2:45 PM ET.

Kezar Life Sciences, Inc., a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders, announced members of the executive team will participate in the following upcoming virtual investor conferences.

Kaleido Biosciences, Inc. (Nasdaq: KLDO), a clinical-stage healthcare company with a differentiated, chemistry-driven approach to targeting the microbiome to treat disease and improve human health, today announced that CEO Dan Menichella will participate in a fireside chat at the Morgan Stanley 19th Annual Virtual Global Healthcare Conference.

Decibel Therapeutics, a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, announced that the Company will participate in the following upcoming virtual investor conferences in September.

Adamis Pharmaceuticals Corporation (Nasdaq: ADMP) today announced the initiation of patient dosing in the Phase 2/3 clinical trial for Tempol, an oral antiviral product candidate, in adult patients with confirmed COVID-19 infection.